Progress of chimeric antigen receptor T cells in the treatment of systemic lupus erythematosus
WEN Shuhua
WANG Tao
WEI Meng
Abstract：Systemic lupus erythematosus(SLE)is an autoimmune disease caused by the immune system's abnormal attack on its own tissues.However,traditional anti-rheumatic drugs and biological agents have poor efficacy for some SLE patients and fail to achieve a sustained remission of the disease.Chimeric antigen receptor T lymphocyte(CAR-T)immunotherapy is currently a hot topic in cellular immunotherapy research,bringing new treatment options for SLE patients.CAR-T immunotherapy has shown faster and more durable efficacy in the clinical application of SLE,and is expected to achieve drug-free remission and reduce the occurrence of adverse events.This article expounds the preclinical and clinical research of CAR-T immunotherapy in SLE at present,and reviews the clinical effect,safety and feasibility of clinical application of CAR-T immunotherapy.
Keywords：systemic lupus erythematosuschimeric antigen receptor T cellchimeric antigen receptor natural killer cellsrheumatic immune disease
Publication Date：2025-08-28
Online Publishing Date：2025-11-25(First online date of this platform, not the publication date of the document)
Pages：7( 602-608 )